Family Support in Transgender and Gender-Diverse Young Adults Seeking Telehealth for Hormone Therapy.

Family support (FS) is a key social determinant of health for transgender and gender-diverse (TGD) young adults. We examined the association between FS and health outcomes in young adults seeking gender-affirming hormone therapy (GAHT) from a US telehealth service. Cross-sectional data from TGD young adults ages 18-24 ( = 7,740) who provided demographic information and information on FS at intake were analyzed.

Erythrocytosis Is Rare With Exogenous Testosterone in Gender-Affirming Hormone Therapy.

Context: Studies have found a variable incidence of erythrocytosis among people using testosterone as part of gender-affirming hormone therapy (GAHT).

Objective: To examine the effect of using exogenous testosterone as GAHT on hematocrit in a large North American cohort.

Methods: We conducted a cross-sectional analysis of testosterone and hematocrit laboratory values in 6670 patients who were prescribed testosterone through Plume, a national provider of GAHT.

Desire for genetically related children among transgender and gender-diverse patients seeking gender-affirming hormones.

Objective: To assess predictors of desire for genetically related children among a national cohort of reproductive-age transgender and gender-diverse patients aged 18 to 44 years initiating gender-affirming hormone therapy for the first time.

Design: Cross-sectional study.

Setting: National telehealth clinic.